Skip to main content

Table 2 Incidence of adverse reactions caused by weekly irinotecan and capecitabine (N = 52)

From: Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients

Adverse reaction

Grade I

Grade II

Grade III

Grade IV

 

Number (%)

Number (%)

Number (%)

Number (%)

Hematologic toxicity

Leukopenia

12 (23.1)

14 (26.9)

5 (9.6)

0 (0)

Neutropenia

9 (17.3)

10 (19.2)

6 (11.5)

3 (5.8)

Febrile neutropenia

3 (5.8)

0 (0)

1 (1.9)

0 (0)

Thrombocytopenia

5 (9.6)

3 (5.8)

0 (0)

0 (0)

Anemia

7 (13.5)

13 (25)

1 (1.9)

0 (0)

Non-hematologic toxicity

Diarrhea

16 (30.8)

5 (9.6)

3 (5.8)

1 (1.9)

Nausea

13 (25.0)

7 (13.5)

2 (3.8)

0 (0)

Vomiting

7 (13.5)

11 (21.2)

2 (3.8)

0 (0)

Anorexia

11 (21.2)

3 (5.8)

0 (0)

0 (0)

Fatigue

11 (21.2)

8 (15.4)

1 (1.9)

0 (0)

Alopecia

5 (9.6)

0 (0)

0 (0)

0 (0)

Hand-foot syndrome

3 (5.8)

0 (0)

1 (1.9)

0 (0)

Oral ulceration

5 (9.6)

1 (0)

1 (1.9)

0 (0)

Venous thrombus

1 (1.9)

0 (0)

0 (0)

0 (0)

Pulmonary infection

1 (1.9)

1 (1.9)

0 (0)

0 (0)

Hyperbilirubinemia

2 (3.8)

0 (0)

0 (0)

0 (0)

Constipation

1 (1.9)

1 (1.9)

0 (0)

0 (0)

Elevated creatinine

1 (1.9)

0 (0)

0 (0)

0 (0)

Elevated blood glucose

1 (1.9)

1 (1.9)

0 (0)

0 (0)

Respiratory alkalosis

1 (1.9)

0 (0)

0 (0)

0 (0)

Pain

3 (5.8)

0 (0)

0 (0)

0 (0)

Hypophosphatemia

0 (0)

0 (0)

1 (1.9)

0 (0)

Hypomagnesemia

0 (0)

1 (1.9)

0 (0)

0 (0)

Hypokalemia

0 (0)

0 (0)

1 (1.9)

0 (0)